Bacterial meningitis is a major health problem worldwide. Even in the developed world, one child in every thousand may contract meningitis before the age of ten [l] . The majority of infections occur in children under five, and the mortality is about 5-10% [l] . In these cases, death occurs soon after the symptoms become apparent. The major causes are Neisseria rneningitidis, Haemophilus influenme type b (Hib) and Streptococcus pneumoniue. The increasing resistance to ampicillin and chloramphenicol among Hib isolates, and penicillin resistance in pneumococci complicates the choice of antibiotic for therapy [2, 3] . Active immunization of children offers the only real long-term solution to reducing the incidence of these infections. Meningococci cause most of the disease in developed countries, but an effective vaccine remains elusive [l] .
5-Enolpyruvylshikimate 3-phosphate synthase (EPSPS), an enzyme from the prechorismate or "shikimate" pathway, has been identified as a target for antibiotic development. This is because this biosynthesis pathway for the essential aromatic amino acids is present in bacteria and fungi (as well as plants) but is absent in vertebrates; thus, compounds inhibiting any one of the enzymes in this pathway would be expected to have minimal side effects in animals or man.
EPSPS catalyses the reversible condensation of phospoenolpyruvate (PEP) and shikimate-3-phosphate (S3P) with the transfer of the carbovinyl group from PEP to S3P to produce 5-enol-pyruvylshikimate-3-phosphate [4] . EPSPS has been shown to be the target of the herbicide glyphosate [5], a competitive inhibitor with respect to PEP. It is therefore conceivable that compounds similar to weed killers might be exploited as antimicrobial drugs, inhibiting EPSPS and thus starving the organism of essential aromatic compounds. In addition, pathogenic bacteria unable to express active EPSPS, ie. which are aroA-, are attenuated for virulence; live attenuated vaccines from these mutants provide immune protection from virulent challenge [6] .
In order to assess the pharmacological suitability of EPSPS inhibitors, we are interested in studying the structure and function of this enzyme. To this end, we are aiming to clone, express and purify this enzyme from the pathogenic bacteria N. meningitidis and H . influenzae. The cloning of the aroA gene from N . meningitidis is of particular interest as it represents an ideal target for the development of an effective live vaccine.
To clone the a r o A gene from N . meningitidis, mixed oligonucleotide primers were designed based on back translation of two highly conserved regions from reported aroA sequences and these were used in a PCR on N. meningitidis chromosomal DNA as template. The PCR product was a 900 bp fragment of the nroA gene, which was cloned in Eschirichia coli and sequenced. This probe was effective in identifying a homologue in a library of N. meningifidis DNA in Lambda ZAP I1 (Stratagene, La Jolla, CA, USA). However, sequencing revealed that although the 3' end of the aroA gene was present, approx. 250 bp at the 5' end were missing from this clone; no clones carrying the entire aroA gene were found. In an alternative apporach, the probe was used to identify by Southern hybridization a variety of restriction fragments of genomic N. meningitidis DNA that carry the aroA gene, but for unknown reasons none of these could be cloned in E. coli. In order to circumvent this problem, an anchor PCR approach was undertaken in which the various restriction fragments, ligated into the cloning vector pUC19, were used as templates. Oligonucleotide primers were designed to bind to regions near the 5' and 3' ends of the determined 900 bp sequence, and these were used in combination with primers that bind to the vector in order to selectively amplify the two ends of the nroA gene. A PCR product was obtained that could be shown to Another PCR product thought to contain the 5' end has also been obtained in low yields, but has yet to be cloned and sequenced for its identity to be confirmed. The sequence determined so far resembles all other known aroA gene products over a wide range of species. The H. influenme aroA gene, which has been cloned and sequenced previously [7] , was subcloned into the inducible expression vector pTrc99A (Pharmacia Biotech, Uppsala, Sweden) and over-expressed in an E. coli aroA-strain (BRD048), yielding soluble and active protein in great abundance. EPSPS activity was assayed as described previously 181. EPSPS was purified by modification of the original procedure for purification of E. coli EPSPS [8, 9] . All steps were carried out at 4 "C unless otherwise indicated. Cell cultures were grown in shaken flasks (225 rpm, 37 "C) in LB medium with ampicillin. Expression was induced at A660 = 0.6 with IPTG (0.2 mg/ml). Cells were grown up overnight and harvested by centrifugation, yielding approx. 8 g of cell pellet (wet weight) per litre culture. After storage at -70 "C, the cell paste was thawed and resuspended in three volumes of extraction buffer (50 mM NaCl in stock buffer: 50 mM potassium phosphate buffer pH 7.0, 1 mM EDTA, 0.4 mM DTT) and then sonicated for 90 s in total at max. 8 "C. The whole cell lysate was further diluted with two volumes of extraction buffer, stirred with approx. 0.5 mg DNAse for 1 h, and centrifuged at 40000 g for 30 min to remove cell debris. The crude extract contained approx. 70 mg protein per gram cells (wet weight). In preparation for hydrophobic interaction chromatography, the crude extract was made 60% in ammonium sulphate by dilution with stock buffer, and the precipitated protein removed by centrifugation at 20000 g for 15 min. The supernatant, which contained more than 95% of the EPSPS activity, was brought to 2 M ammonium sulphate and pH 7.0 by adding KOH, and was loaded onto a column (2.6 x 10 cm) containing Phenyl Sepharose 6 Fast Flow (low sub) equilibrated with 2 M ammonium sulphate in stock buffer. EPSPS activity was eluted with a reverse gradient of 500 ml between 2 M and 0 M ammonium sulphate. An aliquot of the most active fractions was exchanged into stock buffer on a Sephadex G-25 Superfine column and then loaded onto a Mono Q HR 5/5 column equilibrated with stock buffer and eluted with a linear gradient of 20 ml between 0 mM and 200 mM KCl. EPSPS elutes in greater than 95% purity as judged from analysis by SDS-PAGE and Coomassie staining. The purification is summarized in Table 1 .
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